CEO Emmes & PE Board Advisor
Peter is an accomplished drug developer and innovative senior pharmaceutical executive who is currently the CEO of Emmes as well as advising boards, private equity investors, and leaders across the pharmaceutical and biotech industry. He has extensive global experience across a broad range of therapeutic areas, including oncology, immunology, neuroscience, vaccines, anti-infectives, cardiovascular and retinal gene therapy - from First in Human to Medical Affairs.
In his current role as CEO of Emmes, he is responsible for setting both the strategic direction and the day-to-day operations of the full service CRO operating in 30+ countries and across multiple disease areas including ophthalmology, vaccines, rare disease, cell & gene therapy, and neuroscience. Emmes is collaborating with more than 210 sponsors, within the pharmaceutical/biotech industry, government, including over a dozen institutes of the National Institutes of Health (NIH), academic organizations, and non‐profit foundations.
Until January 2023, Peter was the Head of Global Development at Janssen R&D where he was responsible for leading the Global Development organization (including statistics, clinical pharmacology, clinical operations, data operations, project and portfolio management, etc.) in support of delivering a broad ranging portfolio of 450+ studies across all therapeutic areas and all phases from PhI -IV. In this role he managed a 10,000+ globally distributed organization and a $2bn+ operating budget to support the design of innovative drug development programs and the implementation of innovative approaches to trial design and execution including trial virtualization, digital health, patient-centered research, and diversity in clinical trials.
Prior to joining Janssen in 2017, Peter was the Senior Vice President of Global Clinical Operations at Bristol Myers-Squibb where he had spent 14 years holding positions of increasing leadership scope in Medical Affairs, Regulatory Operations and R&D Operations. He also served on the TransCelerate Biopharmaceutical Board of Directors. Prior to joining BMS, Peter was a consultant with Accenture, focusing on post-merger integration of R&D organizations. He is a graduate of Nottingham University in the UK and lives in Chester, NJ.